- FDA Critical Path Initiative
- Critical Path Institute and FDA biomarker qualification
- Biomarkers as drug development tools in rare disease
- Identifying where AI can enhance clinical trial processes for rare disease programs
- Overviewing common challenges when introducing AI to clinical processes
- Successfully implementing AI within teams to avoid delays and implementation challenges
- Building Cross-Functional Leadership: Developing “T-shaped” talent with end-to-end operational vision.
- Proactive Risk Management: Systematically anticipating and mitigating clinical trial risks.
- Strategic Partnership with CROs: Redefining sponsor-CRO collaboration beyond transactional outsourcing.
- From Trial Data to Market Value: Making clinical quality the cornerstone of biotech IPO credibility.
- 构建跨职能领导力： 培养具备端到端（全流程）运营视野的“T型”复合型人才。
- 前瞻性风险管理： 系统性地预测并缓解临床试验过程中的潜在风险。
- 与 CRO 的战略合作伙伴关系： 重新定义申办方与 CRO 的合作模式，摆脱单纯的“交易型外包“。
- 从试验数据到市场价值： 让临床质量成为生物医药企业 IPO（上市）公信力的基石。
